Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107047 | 0.91 | GPR119 (0.51) | GPR119CYP2C9KCNH2NR1H2NR1H3 | |
| SCHEMBL10107988 | 0.86 | GPR119 (0.43) | GPR119CYP2C9KCNH2NR1H2NR1H3 | |
| SCHEMBL10107002 | 0.85 | GPR119 (0.54) | GPR119 | |
| SCHEMBL10107745 | 0.82 | GPR119 (0.54) | GPR119 | |
| SCHEMBL10107852 | 0.82 | GPR119 (0.56) | GPR119 | |
| SCHEMBL10107879 | 0.81 | GPR119 (0.42) | GPR119KCNH2NR1H2NR1H3 | |
| SCHEMBL12170494 | 0.81 | GPR119 (0.47) | GPR119CYP2C9KCNH2NR1H2NR1H3 | |
| SCHEMBL12170476 | 0.81 | GPR119 (0.47) | GPR119CYP2C9KCNH2NR1H2NR1H3 | |
| SCHEMBL10107054 | 0.80 | GPR119 (0.57) | GPR119 | |
| SCHEMBL14870764 | 0.80 | GPR119 (0.41) | GPR119CYP2C9KCNH2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | GPR119 1/4885CYP2C9 999/4885KCNH2 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.